Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Glaucoma
Interventions: timolol maleate and dorzolamide hydrochloride; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hypertension, Renal
Interventions: MLS-101 (Part I), Placebo (Part I), Placebo (Part II), MLS-101 (Part II); Drug · Other
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 44
States / cities: Lincoln, California • Torrance, California • Tustin, California + 38 more

Conditions: Primary Aldosteronism, Resistant Hypertension, Secondary Hypertension, Hyperaldosteronism, Mineralocorticoid Excess, Hypertension
Interventions: Best Practice Advisory Computerized Alert; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 12,501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dyslipidemia, Hypertension, Obesity & Overweight
Interventions: Nutrition education and produce prescription card; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 2 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Eye Disease, Eye Care
Interventions: tailored newsletter, targeted newsletter; Behavioral
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 65 Years and older
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pulmonary Arterial Hypertension
Interventions: (-)-Epicatechin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Ocular Hypertension, Primary Open Angle Glaucoma
Interventions: Latanoprost ophthalmic solution, AKB-9778 4%, Placebo; Drug
Lead sponsor: EyePoint Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 21
States / cities: Inglewood, California • Mission Hills, California • Newport Beach, California + 18 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: Travoprost; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Call For Details, Nebraska

Conditions: Hypertension
Interventions: Determine the presence of Human sequence Ang-(1-12) on no medication, Human sequence Ang-(1-12) on Lisinopril 40mg every day; Other · Drug
Lead sponsor: Trinity Hypertension & Metabolic Research Institute; Other
Eligibility: 40 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Carrollton, Texas

Conditions: Subarachnoid Hemorrhage, Hypertension
Interventions: Clevidipine butyrate injectable emulsion; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Glaucoma, Ocular Hypertension
Interventions: Brimonidine ophthalmic solution 0.1%, Brimonidine ophthalmic solution 0.2%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Renal Artery Obstruction, Hypertension, Renal
Interventions: Herculink Elite Renal Stent System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Santa Clara, California

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Wills Eye; Other
Eligibility: 10 Years to 90 Years
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 65 Years and older
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Prescribing Decisions, Diabetes, Multimorbidity, Hypertension, Geriatrics
Interventions: Clinical Decision Framework for Managing older adults' chronic conditions during hospitalization.; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: High Blood Pressure, Substance Abuse
Interventions: Usual Care, Contingency Management; Other · Behavioral
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Hypertension, Brain Tumor, Epilepsy
Interventions: Clevidipine; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension, Mild Cognitive Impairment
Interventions: Mindfulness and DASH Diet Education, Education group; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 65 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hypertension
Interventions: Azilsartan medoxomil, Valsartan, Olmesartan, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 86
States / cities: Alabaster, Alabama • Ozark, Alabama • Green Valley, Arizona + 83 more

Conditions: Acute Ischemic Stroke, Hemorrhagic Stroke
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Glaucoma, Open-Angle, Glaucoma; Drugs
Interventions: dorzolamide/timolol; Drug
Lead sponsor: CT Glaucoma Associates; Other
Eligibility: 25 Years to 90 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Norwalk, Connecticut

Conditions: Heart Failure With Reduced Ejection Fraction, Pulmonary Hypertension, Right Heart Failure Due to Left Heart Failure
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Portal Hypertension, Liver Diseases, Ascites Hepatic, Hydrothorax, Vascular Diseases
Interventions: Scorpion Portal Vein Access Kit, Cook Transjugular Liver Access Set, Transjugular Intrahepatic Portosystemic Shunt (TIPS); Device · Procedure
Lead sponsor: Argon Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: Atlanta, Georgia • New York, New York • Chapel Hill, North Carolina

Conditions: Hypertension, African Americans, Diet, Carbohydrate-Restricted, Risk Reduction Behavior
Interventions: Very low carbohydrate diet, Standard DPP-GLB diet, Standard DPP-GLB program modules; Other · Behavioral
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 74 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension

Impact of a Produce Prescription Program and Nutrition Education Intervention on Cardiovascular Health in Youth

Tailored Messages to Increase Eye Examination Behavior

(-)-Epicatechin and Pulmonary Arterial Hypertension

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension

Chymase Angiotensin-(1-12) Axis In Hypertensive Disease

Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage

Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension

The HERCULES Trial - A Safety and Effectiveness Study of the Herculink Elite Renal Stent to Treat Renal Artery Stenosis

Building a Database of Results From People Without Eye Problems

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

Optimizing Prescribing Decisions for Hospitalized Older Adults With Chronic Conditions

Improving Antihypertensive Medication Adherence

A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients

Brain Connections and Blood Pressure

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Mapping the Natural History of Parenychymal and Cerebral Perfusion Changes in Acute Ischemic and Hemorrhagic Strokes

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure

Achieving Portal Access With Scorpion Post-Approval Study (APASS)

Giving a Low Carbohydrate Diet to Overcome Hypertension